Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 653 trials

Multifocal Motor Neuropathy: DNTH103 Treatment Study

We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.

Multifocal Motor Neuropathy1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Hypochondroplasia: Vosoritide Treatment Study

We are testing a new medication, vosoritide, to see if it helps children with hypochondroplasia grow taller compared to a placebo. The study aims to evaluate its effects on growth velocity and height.

Hypochondroplasia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatrics

RSV Vaccine Study for Immunocompromised Adults

We are studying how well the RSV vaccine works and its safety in immunocompromised patients aged 18 and older. This includes comparing the immune response after one and two doses of the vaccine.

Respiratory Syncytial Virus (RSV)1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementInfectious DiseasesInternal MedicinePulmonology

Chronic Spontaneous Urticaria: Barzolvolimab Study

We are investigating whether barzolvolimab can help patients with chronic spontaneous urticaria who still experience symptoms despite antihistamine treatment. The study aims to see if it reduces itching and hives compared to a placebo.

Chronic Spontaneous Urticaria1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementAllergologyDermatology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Type 1 Diabetes: Diamyd® Treatment Study

We are evaluating the safety and feasibility of Diamyd® injections in young people at risk for Type 1 diabetes. This study looks at how the treatment affects their immune system and progression of the disease.

Type 1 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Renal Impairment: Enpatoran Study

We are investigating how kidney function impacts the way the drug Enpatoran is absorbed and used in the body. This study aims to improve treatment for patients with renal impairment.

Healthy Participants1-2 yearsSafety phase (I)Internal MedicineNephrology

Cardiovascular Disease Prevention: Personalized Statin Therapy

We are studying whether statin treatment guided by genetic risk can lower heart disease events in individuals at high risk. The trial will also look at how well patients accept this personalized approach and its effects on their health.

High Genetic Risk for Coronary Artery Disease1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Omalizumab Withdrawal in Severe Allergic Asthma

We are studying whether stopping Omalizumab after long-term treatment is as effective as continuing it for patients with well-controlled severe allergic asthma. This trial aims to assess asthma control and quality of life over time.

Allergic Asthma1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Amlitelimab: Effects on Medication Processing

We are investigating how amlitelimab influences the way the body handles specific medications. This study aims to improve safety for patients taking multiple drugs.

Atopic Dermatitis1-2 yearsSafety phase (I)DermatologyInternal Medicine

Advanced Solid Tumors: MOMA-313 Oral Medication

We are studying an oral treatment called MOMA-313 for individuals with advanced or metastatic solid tumors. The goal is to learn more about its effects and potential benefits.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Oncology

Polymyalgia Rheumatica: Rituximab Study

We are investigating whether rituximab can help reduce the need for corticosteroids in people with relapsing polymyalgia rheumatica. This study compares rituximab to a placebo to assess its effectiveness.

Polymyalgia Rheumatica1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyRheumatology

BI 3804379: Tolerance Study in Healthy Volunteers

We are testing how well different doses of BI 3804379 are tolerated by healthy people. This study aims to gather important safety information for future use in patients.

Healthy Volunteers1-2 yearsSafety phase (I)

Gastric Bypass Surgery: Tranexamic Acid Study

We are investigating whether giving Tranexamic acid during gastric bypass surgery helps reduce bleeding in patients with morbid obesity. This could lead to safer surgical procedures.

Morbid Obesity1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOrthopedics and Traumatology

Generalized Anxiety Disorder: MM120 Medication Study

We are testing a new oral medication, MM120, to see if it helps reduce anxiety symptoms in adults with generalized anxiety disorder. The study will also look at its effects on quality of life and sexual functioning.

Generalized Anxiety Disorder1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemotePsychiatry

Hernia Repair: Comparing Pain Relief Techniques

We are studying whether giving a specific pain relief injection before or after hernia surgery helps reduce chronic pain and the need for pain medications. This trial is for patients undergoing open inguinal hernia mesh repair.

Chronic Pain After Hernia Surgery1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and Traumatology

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Ataxia Telangiectasia: EryDex Safety Study

We are assessing the safety and tolerability of EryDex in individuals with Ataxia Telangiectasia. Additionally, we’re exploring its potential effects on neurological symptoms.

Ataxia Telangiectasia (A-T)1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Glioblastoma: Radioimmunotherapy with Lutetium 177

We are investigating a new treatment using a targeted antibody for patients with glioblastoma. The study aims to determine the right dose and assess its safety and effectiveness.

Glioblastoma1-2 yearsSafety phase (I)NeurologyOncology